Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
BW Businessworld

Mankind Pharma Launches Infertility Drug

The company has become the first Indian and second global firm to develop the drug, it claims.

Photo Credit :

1455122342_bpHFlG_drug.jpg

One of the leading pharmaceutical firms in India - Mankind Pharma- on December 5 launched a new “Dydrogesterone-containing drug” to treat infertility. The drug uses the molecule, Dydrogesterone to treat progesterone deficiency leading to recurrent miscarriage during pregnancy.

The manufacturing process of Dydrogesterone is very complex as it involves conversion of natural progesterone, the company said.

Mankind, which has a strong presence in pharmaceutical, veterinary, OTC & FMCG segments, is present across North America, Asia, Africa and CIS countries. It is known for some of the widely advertised Over-the-Counter brands including Manforce condoms, Preganews, a pregnancy test card endorsed by Bollywood actress Kareena Kapoor Khan, AcneStar, an anti-inflammatory and anti-bacterial gel, Gas-O-Fast, a product to tackle acidity, heartburn and hyperacidity, Adiction Deodorant and several more well-recognized brands.

When asked about the new drug, Founder of Mankind Pharma, RC Juneja said, “Only after surpassing the process of clinical trials and various lab tests of six months, we came to this conclusion that Dydroboon is as safe and effective as other drugs available in the market.” For the past nine years, the team of 400 scientists have been working on the project to research and develop this first in India and second across globe drug for the sensitive market of infertility, said Juneja.

Earlier, the company was not ruled under the patent laws however, in 2005, they have become a part of it. This has helped Mankind to benefit the end users by reducing the input cost, resulting in scaled down prices. To fulfill the demand of the people, Mankind has shifted its concentration from acute diseased drugs to lifestyle disease drugs.


sentifi.com

Top themes and market attention on: